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The human ether-à-go-go-1 (h-eag1) voltage-dependent K + channel is necessary for cell cycle progression and its overexpression stimulates tumorigenesis. We report here that h-eag1 expression is controlled by the p53−miR-34−E2F1 pathway through a negative feed-forward mechanism: p53
transactivates miR-34 that directly represses h-eag1 at post-transcriptional level and indirectly downregulate h-eag1 at transcriptional level through repressing E2F1. Thus, inhibition of p53 causes oncogenic overexpression of h-eag1 or overexpression of h-eag1 fulfills the oncogenic effect of p53 inactivation.
Abnormally enhanced proliferation often causes loss of control of cell growth leading to tumorigenesis or cancer formation. Several fundamental steps need to be fulfilled at the cellular level for tumorigenesis and these steps can be roughly viewed as characteristic alterations of some physicochemical processes:
(1) cell volume, (2) intracellular Ca
2+
, and (3) intracellular pH. Evidence has emerged indicating a deregulated expression of ion channel protein-coding genes as well as ion channel malfunction as an important step in the development and progression of cancers. The ion channels critically related to cell proliferation and cancer are the K + channels 1, 2 .
Of various categories of K + channels, the ether à go-go (eag) voltage-dependent K + channel family stands out the most attractive one in relation to tumor generation, progression and metastasis 1, 2 . Eag1 (or Kv10.1 encoded by KCNH1), the founding member of the eag family, is restricted in its expression to the brain and placenta in the process of myoblast fusion, indicating that the channel is not normally expressed in differentiated peripheral tissues. On the contrary, eag1 is expressed in a variety of cell lines derived from human malignant tumors and in clinical samples of several different cancers [3] [4] [5] [6] [7] , while the surrounding tissues are devoid of eag1 expression. In these cell lines, eag1 enhances the proliferation of the cells, and is required for the maintenance of growth. One of the most intriguing aspects of human eag1 (h-eag1) channels is its relationship to cellular transformation; h-eag1 channels are necessary for progression through the G 1 phase and G 0 /G 1 transition of the cell cycle. Cells transfected with h-eag1 are able to grow in the absence of serum, lose contact inhibition, and induce aggressive tumors when implanted into immune-depressed mice 7 . Moreover, specific inhibition of eag1 expression by antisense technique 7 , siRNA or antibody 8 leads to a reduction in tumor cell proliferation in vitro and in vivo.
In an initial effort to understand the molecular mechanisms for oncogenic overexpression of eag1 in cancer cells, we characterized the promoter region of the gene. We used 5'RACE to identify the transcription start site (TSS) which was found located to 152 bp upstream the translation start codon (ATG) of h-eag1 (GenBank accession No. DQ120124) (Fig. 1S) . We then defined the minimal promoter region by luciferase reporter gene assay (Fig. 2S) . Computer analysis revealed consensus sequences for E2F1, AP2, and SP1 within the core promoter region (position -630/+114), which might act as transactivators of h-eag1 gene. Using the decoy oligodeoxynucleotide (dODN) approach 9 , which contains the perfect binding site for the target transcription factor and can sequestrate the target leading to reduction of transcriptional activity (Supplementary Materials online), we revealed a significant role of E2F1, but not of SP1 and AP2, in driving the core promoter activity (Fig. 1A) . Mutation of the E2F1 cis-element rendered a loss of luciferase activity of the core promoter. We further verified E2F1 as a key factor in activating h-eag1 transcription: E2F1-dODN decreased h-eag1 mRNA level by ∼80% in SHSY5Y human neuroblastoma cells (Fig. 1B) . With qPCR, we have also ruled out the role of SP1 and AP2 in transcriptional activation of h-eag1 (Fig. 1B) . Transfection of E2F1 plasmid, on the other hand, increased h-eag1 mRNA level by as much as 8 folds, which was diminished by E2F1-dODN. As a negative control, transfection of SP1 plasmid did not significantly alter h-eag1 mRNA level ( Fig. 1C) despite that this maneuver was able to enhance expression of h-erg1 at the mRNA level ( Fig. 1C) ,
another member of the eag K + channel gene family, as already established in our previous study 10 . The ability of E2F1 to bind its cis-acting elements in the promoter region of h-eag1 was verified using ChIP and EMSA ( Fig. 1D & 1E) . The transcription factor E2F1 plays a pivotal role in the coordinated expression of genes necessary for cell cycle progression and division, and is known to be an oncoprotein critical for the transcriptional activation of genes that control the rate of tumor cell proliferation 11 . Our finding thus indicates a role of E2F1 in oncogenic upregulation of h-eag1 expression at the transcriptional level.
Recently, microRNAs (miRNAs) have emerged as a new class of regulators of gene expression.
These small non-protein-coding mRNAs primarily elicit repression of protein translation by a partial complementary mechanism with its 5'end 2-8 nts, the "seed site", base-paring the sequence motif(s) in the 3'UTR of target genes. We investigated if h-eag1 is regulated at the post-transcriptional level by miRNAs. We first performed computational prediction of h-eag1 as a target for miRNA regulation. And we identified multiple binding sites for a tumor-suppressor miRNA subfamily miR-34 (including miR34a, miR-34b and miR-34c) in the 3'UTR of h-eag1 mRNA (Fig. 3S) . To experimentally establish miR- (Fig. 1G) . The same observations were expanded to miR-34b and miR-34c (Fig. 5S) . Intriguingly, reduction of h-eag1 expression was also seen at the mRNA level (Fig. 1H) . As a negative control, miR-1 did not cause any appreciable effects on h-eag1 expression.
It has been documented that miR-34a directly targets the mRNA encoding E2F1 and significantly reduces the levels of E2F1 and E2F3 proteins 12, 13 . Furthermore, miR-34a expression increases during retinoic acid induced differentiation, whereas E2F1 protein levels decrease 12 . We confirmed that transfection of miR-34a reduced E2F1 protein levels by ~68% in SHSY5Y cells (Fig. 1I) and the same results were obtained with miR-34b and miR-34c (Fig. 5S & 6S) . Moreover, application of the MT-AMO caused significant increases in the protein levels of E2F1 (Fig. 1I ) and h-eag1 (Fig. 1G) . These results indicate that miR-34 regulates h-eag1 expression through at least two mechanisms. First, miR-34 directly represses h-eag1 protein. Second, miR-34 represses E2F1 protein, leading to reduced transcription of h-eag1. This latter effect also explains the effectiveness of miR-34 to decrease h-eag1
mRNA. This is supported by the experiments showing the lack of effects of miR-34a on h-eag1 transcript level in cells co-transfected with the E2F1-carrying vector that doe not contain the 3'UTR of E2F1 gene (Fig. 1J) .
miR-34 has been known to be a direct transcriptional target of p53 13, 14 and to mediate the apoptotic action of p53 15 . Thus, changes of p53 activity are deemed to change the level of miR-34 thereby those of E2F1 and h-eag1 as well. Indeed, p53 activation by Mdm2 inhibitor nutlin-3 (1 μM) increased miR-34 level ( Fig. 2A) , and simultaneously decreased E2F1 and h-eag1 protein levels (Fig. 2B) and h-eag1 mRNA concentration (Fig. 2A) . These changes were abrogated when the MT-AMO was co-applied with Nutlin-3. Pifithrin-alpha (PFT-α; 30 μM), the p53 inhibitor, produced exactly the opposite effects to p53
activator. Evidently, p53 negatively regulates expression of h-eag1. Moreover, in the presence of p53
inhibitor, exogenously applied miR-34a retained the full ability to downregulate E2F1 ( Fig. 2C & 2D) and h-eag1 ( Fig. 2E & 2F) , suggesting that miR-34 mediates the regulatory role of p53 on E2F1 and heag1. Furthermore, in the presence of both p53 inhibitor and the MT-AMO, h-eag1 expression was markedly upregulated at both mRNA and protein levels, but the E2F1-dODN abolished these increases ( Fig. 2G & 2H) . On the other hand, the downregulation of h-eag1 expression induced by co-application of p53 activator and miR-34a was abolished by E2F1 overexpression (Fig. 2I & 2J) .
Together with the results described above, it is clear that h-eag1 is a terminal effecter component in the p53−miR-34−E2F1 pathway for expression regulation and functional signaling. When p53 activity increases in response to environmental and cellular stresses, miR-34 is deemed to increase, and the increased miR-34 will decrease E2F1 to diminish h-eag1 gene transcription and will also repress h-eag1 protein translation as well; diminishment of h-eag1 expression and function then results in a shut-down of cell proliferation or a cell cycle arrest. This implies that h-eag1 executes the cell-cycle checkpoint signal from p53 transmitting along the p53−miR-34−E2F1−h-eag1 pathway (Fig. 7S) . Indeed, expression of h-eag1 is cell cycle-related; upon synchronization of the cells in G 1 phase with retinoic acid, eag current amplitude decreased to less than 5% of the control 16 . And retinoic acid has been showed to stimulate expression of miR-34a accompanied by a decrease in E2F1 protein level 12 .
Next, we sought to examine this notion with the following approaches. We first demonstrated that activation of p53 induced a cell growth arrest in SHSY5Y cells, and overexpression of E2F1 alleviated the cell growth inhibition and so did transfection with the MT-AMO to knock down miR-34 (Fig. 3A) .
We then observed that the direct growth-stimulating effect of E2F1 was remarkably attenuated by inhibition of h-eag1 with the antisense oligodeoxynucleotides directed against h-eag1 gene but not by the sense oligomer for negative control (Fig. 3B) .
The human eag-related K + channel h-erg1 has also been frequently implicated in tumorigenesis 17, 18 .
To see if h-erg1 is also a part of the p53 network, we analyzed the promoter region that we identified previously 10 and the 3'UTR of the h-erg1 gene. We found a nearly perfect putative E2F cis-element within the core promoter region (Fig. 8S) and multiple binding sites for miR-34a, miR-34b and miR-34c
in the 3'UTR of the h-erg1 mRNA (Fig. 3S) . We further established the role of E2F1 in stimulating herg1 transcription and the role of miR-34 in repressing h-erg1 translation (Fig. 9S) . These findings indicate that in addition to h-eag1, h-erg1 is also a component of the p53−miR-34−E2F1 pathway.
The tumor-suppressor gene p53 and its downstream genes consist of a complex molecular signaling network and p53 is at the center of this network regulating diverse physiological responses to cancerrelated stresses. Activated p53 in response to DNA damage or oncogene activation induces cell cycle arrest, which can be transient or permanent (senescence), or promotes apoptosis in cases where the damage is too severe; conversely, inactivation of p53 causes oncogenic cell growth. Our study herein revealed that miR-34, a known transcriptional target of p53, is an important negative regulator of h-eag1 through dual mechanisms by direct repression at the post-transcriptional level and indirect silencing at the transcriptional level via post-transcriptionally repressing E2F1 that we have established to be a transactivator of h-eag1. p53 activates miR-34 transcription; upregulation of miR-34 represses E2F1 and h-eag1; repression of E2F1 downregulates expression of h-eag1. Therefore, p53 negatively regulates heag1 expression by a negative feed-forward mechanism through the p53−miR-34−E2F1 pathway and inactivation of p53 activity as it is the case in many cancers can thus cause oncogenic overexpression of h-eag1 by relieving the negative feed-forward regulation. These findings not only help us understand the molecular mechanisms for oncogenic overexpression of h-eag1 in tumorigenesis but also uncover a new layer of mechanisms underlying cell-cycle regulation by the p53−miR-34−E2F1−h-eag1 pathway.
Moreover, these findings place h-eag1 in the p53−miR-34−E2F1−h-eag1 pathway with h-eag as a terminal effecter component and with miR-34 (and E2F1) as a linker between p53 and h-eag1. Our study therefore fills a gap between p53 pathway and its cellular function mediated by h-eag1.
Note: Supplementary Information is available on the Nature Cell Biology website. 
